Cargando…
A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice
The use of C3d, the final degradation product of complement protein C3, as a “natural” adjuvant has been widely examined since the initial documentation of its immunogenicity-enhancing properties as a consequence of binding to complement receptor 2. Subsequently it was demonstrated that these effect...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849677/ https://www.ncbi.nlm.nih.gov/pubmed/29017821 http://dx.doi.org/10.1016/j.imbio.2017.10.002 |